Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07090161
Recruiting Phase 2

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

NCT07090161 · tracked via the Priya Life Science USA tracker
Sponsor
Vanda Pharmaceuticals
Phase
Phase 2
Started
2025-09-15
Last updated
2026-02-27

Condition(s) studied

HypertensionUncontrolled Hypertension

Investigational drug(s) / intervention(s)

iloperidone →Placebo

iloperidone: iloperidone

Placebo: placebo comparator

Study summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * SiSBP \>/= 130 mmHg despite \>8 weeks treatment w/ 1 or more antihypertensive therapies Exclusion Criteria: * Confirmed Grade 3/severe hypertension (SiSBP \>/= 180 mmHg, SiDBP \>/= 120 mmHg), unstable cardiac disease, renal insufficiency

Primary outcome measure(s)

  • Change from baseline to treatment week 4 in SiSBP — screening to treatment week 4

Trial sites (28)

FacilityCityRegionStatus
Vanda Investigative Site Phoenix Arizona Not Yet Recruiting
Vanda Investigative Site Tempe Arizona Recruiting
Vanda Investigative Site Tucson Arizona Not Yet Recruiting
Vanda Investigative Site Chula Vista California Recruiting
Vanda Investigative Site Dublin California Recruiting
Vanda Investigative Site Valencia California Not Yet Recruiting
Vanda Investigative Site Walnut Creek California Recruiting
Vanda Investigative Site Doral Florida Not Yet Recruiting
Vanda Investigative Site Fort Myers Florida Recruiting
Vanda Investigative Site Columbus Georgia Recruiting
Vanda Investigative Site Oak Brook Illinois Recruiting
Vanda Investigative Site Tinley Park Illinois Recruiting
Vanda Investigative Site El Dorado Kansas Recruiting
Vanda Investigative Site Wichita Kansas Recruiting
Vanda Investigative Site Lexington Kentucky Recruiting
Vanda Investigative Site Hazelwood Missouri Recruiting
Vanda Investigative Site Las Vegas Nevada Not Yet Recruiting
Vanda Investigative Site Mount Kisco New York Not Yet Recruiting
Vanda Investigative Site Rochester New York Not Yet Recruiting
Vanda Investigative Site Kinston North Carolina Recruiting
Vanda Investigative Site Cincinnati Ohio Recruiting
Vanda Investigative Site Norman Oklahoma Recruiting
Vanda Investigative Site Oklahoma City Oklahoma Not Yet Recruiting
Vanda Investigative Site Charleston South Carolina Recruiting
Vanda Investigative Site Carrollton Texas Not Yet Recruiting
Vanda Investigative Site Salt Lake City Utah Not Yet Recruiting
Vanda Investigative Site Burke Virginia Recruiting
Vanda Investigative Site Norfolk Virginia Recruiting

More Vanda Pharmaceuticals trials in the USA

Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances Recruiting
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Recruiting
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection Enrolling by invitation
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies Recruiting
Patient Registry of Blind Subjects With Sleep-related Problems Recruiting

Other trials for the same condition

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension Recruiting
Global Paradise System US Post Approval Study Recruiting
RADIANCE Continued Access Protocol Active, not recruiting
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran Recruiting
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR) Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07090161 on ClinicalTrials.gov ↗ ← All trials in the USA